To protect Europeans from the risks posed by artificial intelligence, the EU passed its AI Act last year. This month, the EU released a Code of Practice to help providers of general purpose AI comply with the AI Act. This blog reviews the measures set out in the new Code’s safety and security chapter, assesses how they compare to existing practices, and what the Code’s global impact might be.

Opposing narratives around AI for biotechnology raise the question: how are biotech researchers actually using AI in published research? CSET’s Steph Batalis, Catherine Aiken, and James Dunham explored this question by leveraging CSET’s merged academic corpus, enriched publication metadata, and research clusters.

Artificial intelligence is becoming more integrated into the sciences. One of the scientific fields experiencing this is computational biology, which uses computer modeling to understand biological mechanisms and systems. This blog post provides an understanding of important research trends in these subject areas, and how advancements in AI can improve the speed and efficiency of computational biology to improve human health and well-being.

This blog post analyzes five major Chinese AI governance proposals, focusing on the key actors specified in each proposal. We find that older proposals lack specificity when identifying AI governance actors. Recent proposals, on the other hand, assign roles and responsibilities to a defined set of actors. The findings from this blog post can help policymakers and analysts better understand China’s fast-evolving AI governance landscape.

The European Union's Artificial Intelligence Act has officially come into force today after more than five years of legislative processes and negotiations. While marking a significant milestone, it also initiates a prolonged phase of implementation, refinement, and enforcement. This blog post outlines key aspects of the regulation, such as rules for general-purpose AI and governance structures, and provides insights into its timeline and future expectations.

Now that the first set of milestones has passed for the Biden administration’s October 2023 executive order on artificial intelligence, where do things stand for biotech? This blog post gives an overview of the most recent action items, with a recap of expert commentary from CSET’s June 2024 Webinar on the AIxBio Policy Landscape.

As the U.S. government considers banning genomics companies from China in the Biosecure Act, it opens a broader question of how the U.S. and other market economies should deal with China’s national champions. This blog post provides an overview of BGI and how China’s industrial policy impacts technology development.

As the U.S. government tightens its controls on China’s semiconductor ecosystem, a new dimension is increasingly worrying Congress: the open-source chip architecture known as RISC-V (pronounced “risk-five”). This blog post provides an introduction to the RISC-V architecture and an explanation of what policy-makers can do to address concerns about this open architecture.

This guide provides a run-down of CSET’s research since 2019 for first-time visitors and long-term fans alike. Quickly get up to speed on our “must-read” research and learn about how we organize our work.

The recent Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence will have major implications for biotechnology. The EO demonstrates that the White House considers biorisk a major concern for AI safety and security. In this blog post CSET’s bio experts explain the bio-relevant takeaways of the executive order, add some additional context, and note their remaining questions about its implementation.